We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
GSK plc | NYSE:GSK | NYSE | Depository Receipt |
Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.23 | 0.53% | 43.58 | 43.68 | 43.27 | 43.58 | 4,048,068 | 01:00:00 |
By Cecilia Butini
GlaxoSmithKline PLC said Friday that a Covid-19 vaccine developed with South Korea-based SK Bioscience Co. has met its co-primary objectives in a Phase 3 study, demonstrating superior antibody levels compared with AstraZeneca PLC's shot, which was chosen as a control vaccine.
The British pharmaceutical major said that the vaccine, which is called SKYCovione and uses Glaxo's adjuvant technology, showed a clinically acceptable safety profile, with most postvaccine adverse reactions being mild or moderate.
SK Bioscience will apply for emergency-use listing with the World Health Organization and authorization at individual regulatory agencies around the world. The company had already signed an advance purchase agreement with South Korea for a total of 10 million doses, Glaxo said.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
April 29, 2022 04:08 ET (08:08 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions